Actively Recruiting
Association Between Cytokines Gene Single Nucleotide Polymorphisms and Type 2 Inflammatory Asthma in Children
Led by Guangzhou Institute of Respiratory Disease · Updated on 2025-02-21
300
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating how genetic differences called single nucleotide polymorphisms (SNPs) affect children with type 2 inflammation-related asthma. This observational study compares children diagnosed with asthma who show signs of type 2 inflammation to healthy children. The goal is to better understand how these genetic variations influence asthma development and to support personalized treatment and prevention strategies. The study includes two groups: children with asthma who meet specific inflammation criteria and healthy children. Researchers measure several type 2 inflammation markers, such as the fraction of exhaled nitric oxide, blood eosinophil counts, sputum eosinophil percentages, and serum immunoglobulin E levels. They also assess lung function through tests like forced expiratory volume in one second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, and peak expiratory flow (PEF). Genetic testing for SNPs is performed to explore differences between groups. Participants will be evaluated during outpatient visits, where lung function tests and inflammation marker measurements will be collected. The main outcomes include type 2 inflammation indicators, pulmonary function measures, and genetic polymorphism data. This process helps researchers identify risk factors and differences in asthma linked to genetics, with the study lasting until December 2025.
CONDITIONS
Brief Title
Association Between Genetic Polymorphisms and Type 2 Asthma in Children
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Children diagnosed with asthma according to the 2023 GINA guidelines
- No other diseases causing wheezing and cough like acute laryngitis, diphtheria, congenital airway abnormalities, or tracheal foreign bodies
- No use of antibiotics or systemic hormone medications in the 2 weeks before hospital visit
- No other complications such as congenital heart disease, pneumonia, gastroesophageal reflux disease, or muscle dysplasia
You will not qualify if you...
- Children who have taken immunosuppressants, antibiotics, or similar drugs for a long time before admission
- Children with primary immunodeficiency disease
- Children and families who do not cooperate or refuse to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants undergo assessments including type 2 inflammation indicators, pulmonary function tests, and genetic testing for single nucleotide polymorphisms.
1 outpatient visit
Duration - Up to 2 years
Participants are observed to compare genetic polymorphisms and inflammatory markers between children with type 2 asthma and healthy controls.
No scheduled visits; observational follow-up
Trial Site Locations
Total: 1 location
1
Guangzhou institute of respiratory disease
Guangzhou, Guangdong, China, 510120
Actively Recruiting
Research Team
L
Lihong Sun, M.D.
L
Lanying Cheng
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here